Alteplase for treating acute ischaemic stroke

use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has acute ischaemic stroke and the healthcare professional responsible for their care thinks that alteplase is the right treatment, it should be available for use, in line with NICE's recommendations. Alteplase for treating acute ischaemic stroke (TA264) 6 Recommendations for further research 6.1 The clinical efficacy and safety of thrombolysis with alteplase for acute ischaemic stroke is being assessed outside of its current marketing authorisation, specifically in patients aged up to 80 years and up to 6 hours from onset of stroke symptoms (the third International Stroke Trial [IST-3]).
